You are here

Therachon

After scoring big Pfizer buyout, a Therachon co-founder turns once again to dwarfism with $24M Series A

After scoring big Pfizer buyout, a Therachon co-founder turns once again to dwarfism with $24M Series A

Endpoints

Flag link:

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

BioCentury

Flag link:

Pfizer agrees on $340M upfront to buy Therachon for dwarfism drug

Pfizer agrees on $340M upfront to buy Therachon for dwarfism drug

Fierce Biotech

short-limbed dwarfism

Flag link: